Cube Labs SpA (MIL:CUBE) Change In Receivables : €-0.03 Mil (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cube Labs SpA Change In Receivables?

Cube Labs SpA's change in receivables for the quarter that ended in Jun. 2023 was €-0.05 Mil. It means Cube Labs SpA's Accounts Receivable increased by €0.05 Mil from Dec. 2022 to Jun. 2023 .

Cube Labs SpA's change in receivables for the fiscal year that ended in Dec. 2022 was €-0.01 Mil. It means Cube Labs SpA's Accounts Receivable increased by €0.01 Mil from Dec. 2021 to Dec. 2022 .

Cube Labs SpA's Accounts Receivable for the quarter that ended in Jun. 2023 was €4.30 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cube Labs SpA's Days Sales Outstanding for the six months ended in Jun. 2023 was 1,043.07.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cube Labs SpA's liquidation value for the six months ended in Jun. 2023 was €1.08 Mil.

Cube Labs SpA Change In Receivables Historical Data

The historical data trend for Cube Labs SpA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cube Labs SpA Change In Receivables Chart

Cube Labs SpA Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

-0.28

-0.87

-0.04

-0.01

Cube Labs SpA Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial			-	-	-0.02	0.02	-0.05

Cube Labs SpA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.03 Mil.

Cube Labs SpA (MIL:CUBE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cube Labs SpA's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.298	/	0.752	*	91
=	1,043.07

2. In Ben Graham's calculation of liquidation value, Cube Labs SpA's accounts receivable are only considered to be worth 75% of book value:

Cube Labs SpA's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.407	-	4.55	+	0.75 * 4.298	+	0.5 * 0
=	1.08

Cube Labs SpA Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cube Labs SpA's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cube Labs SpA (MIL:CUBE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Cube Labs SpA (MIL:CUBE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Giulio Caccini, 1, Rome, ITA, 00186

Website

https://cube-labs.com

Cube Labs SpA operates as a venture builder that enables innovation in the healthcare technology space. The company is engaged in attracting sources of financing and providing entrepreneurial and operational support to the companies to develop healthcare technologies for the market.